Congenital Human Cytomegalovirus and the Complement System

Area of Science:

• Immunology
• Virology
• Developmental Biology

Background:

• Congenital human cytomegalovirus (HCMV) infection is a leading cause of birth defects, affecting 1 in 200 newborns globally.
• While often asymptomatic at birth, congenital HCMV can lead to severe neurodevelopmental sequelae, including microcephaly and sensorineural hearing loss.
• Current therapeutic options for pregnant individuals and preventive vaccines against HCMV are limited, highlighting an urgent need for novel strategies.

Purpose of the Study:

• To review the dual role of the complement system in fetal development and HCMV pathogenesis.
• To propose a hypothesis linking complement system dysregulation to congenital HCMV-related pathogenesis and neurodevelopmental abnormalities.
• To explore therapeutic potential by examining how HCMV perturbs the complement system and the implications of complement inhibition.

Main Methods:

• Literature review synthesizing current knowledge on the complement system's role in fetal development.
• Analysis of existing research on HCMV pathogenesis and its interaction with the innate immune system.
• Exploration of complement system dysregulation as a potential mechanism driving congenital HCMV sequelae.

Main Results:

• The complement system is essential for fetal development and maternal immunity but can contribute to inflammation during HCMV infection.
• HCMV infection may dysregulate the complement cascade, potentially exacerbating fetal damage and neurodevelopmental issues.
• Evidence suggests that targeting the complement system could offer a novel therapeutic approach for congenital HCMV disease.

Conclusions:

• A dysregulated complement system is hypothesized to be a critical factor in the pathogenesis of congenital HCMV infection and its associated neurodevelopmental complications.
• Understanding HCMV's impact on the complement system provides insights into disease mechanisms.
• Targeting the complement system presents a promising avenue for developing new treatments to mitigate the adverse effects of congenital HCMV infection.